ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,214.08
0.51%
Dow Jones
39,387.76
0.85%
US Dollar vs MXN
16.8095
0.09%
Brent Oil
84.215
0.32%
Bitcoin
62,808.28
-0.38%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Janux Therapeutics Inc (JANX)

  7. Janux Therapeutics Inc (JANX) Noticias

JANX

Janux Therapeutics (JANX)

Janux Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:JANX
FechaHoraFuenteTítuloSímboloCompañía
08/05/202408:13Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:JANXJanux Therapeutics Inc
07/05/202415:01Business WireJanux Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:JANXJanux Therapeutics Inc
08/03/202415:47Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:JANXJanux Therapeutics Inc
08/03/202415:23Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:JANXJanux Therapeutics Inc
08/03/202415:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:JANXJanux Therapeutics Inc
08/03/202415:01Business WireJanux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsNASDAQ:JANXJanux Therapeutics Inc
29/02/202416:30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:JANXJanux Therapeutics Inc
29/02/202400:22Business WireJanux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:JANXJanux Therapeutics Inc
28/02/202420:55Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:JANXJanux Therapeutics Inc
27/02/202416:00Business WireJanux Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:JANXJanux Therapeutics Inc
26/02/202415:05Business WireJanux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid TumorsNASDAQ:JANXJanux Therapeutics Inc
20/02/202407:00Business WireJanux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008NASDAQ:JANXJanux Therapeutics Inc
09/02/202415:31Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:JANXJanux Therapeutics Inc
08/01/202408:00Business WireJanux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific OfficerNASDAQ:JANXJanux Therapeutics Inc
03/01/202415:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
03/01/202415:45Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
07/11/202315:19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:JANXJanux Therapeutics Inc
07/11/202315:01Business WireJanux Therapeutics Reports Third Quarter 2023 Financial Results and Business HighlightsNASDAQ:JANXJanux Therapeutics Inc
07/09/202317:14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:JANXJanux Therapeutics Inc
08/08/202315:01Business WireJanux Therapeutics Reports Second Quarter 2023 Financial Results and Business HighlightsNASDAQ:JANXJanux Therapeutics Inc
17/07/202307:45Business WireJanux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsNASDAQ:JANXJanux Therapeutics Inc
17/07/202307:00Business WireJanux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline ProgramsNASDAQ:JANXJanux Therapeutics Inc
23/06/202315:37Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:JANXJanux Therapeutics Inc
16/06/202316:16Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:JANXJanux Therapeutics Inc
05/06/202315:35Business WireJanux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical DevelopmentNASDAQ:JANXJanux Therapeutics Inc
30/05/202315:46Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:JANXJanux Therapeutics Inc
09/05/202316:07Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:JANXJanux Therapeutics Inc
09/05/202315:17Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:JANXJanux Therapeutics Inc
09/05/202315:01Business WireJanux Therapeutics Reports First Quarter 2023 Financial Results and Business HighlightsNASDAQ:JANXJanux Therapeutics Inc
28/04/202316:09Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:JANXJanux Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:JANX

Su Consulta Reciente

AMEX
XLV
Health Care Select Sector
CCOM
OILBRENT
Brent Oil
CCOM
SILVER
SILVER
NYSE
MCD
McDonalds
NYSE
XOM
Exxon Mobil
COIN
BTCUSD
Bitcoin
USOTC
BNPQY
BNP Paribas (QX)
AMEX
SPY
SPDR S&P 500
CCOM
US500
US 500
COIN
SOLUSD
Solana
NYSE
NKE
Nike
AMEX
XLF
Financial Select Sector
NASDAQ
AAPL
Apple
CCOM
US30
US 30
NASDAQ
AMZN
Amazon.com
NYSE
MRK
Merck
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados